Li Dong   Ph. D
	Associate Professor  Master Supervisor
	Email：Dongli@sxu.edu.cn

 

---

Education background

1997/09-2002/07	Medical Bachelor in Preventive Medicine Shenyang   Medical College, Shenyang, China
2002/09-2005/07	Medical Master in Environmental and Occupational Health Tianjin   Medical University, Tianjin, China
2014/09-2017/07	Ph. D in Epidemiology and Biostatistics Peking   Union Medical College, Beijing, China

Work experience

2019/01-2021/09	Post-doctoral Norwegian   Cancer Institute/University of Oslo
2017/07-present	Associate professor Shanxi   University，Institutes of Biomedical Science
2005/08-2014/07	Research   assistant/Associate professor China   Institute For Radiation Protection, Taiyuan, China

Science programs

It is mainly devoted to the pathogenesis and control strategies of infectious diseases, focusing on the etiology, early diagnosis and early treatment of molecular markers of cervical cancer, esophageal cancer and tuberculosis. The specific direction is

l The role of exosome miRNA and protein and immune microenvironment in the pathogenesis of cervical cancer；

l The role of HPV methylation and host methylation in predicting the risk of cervical cancer ；

l Study on the immune regulation of mesenchymal stem cells in drug-resistant tuberculosis；

l The early warning mechanism of digestive tract microbial genome in the formation of esophageal cancer.

Hosted research projects in the recent five years

1. National Natural Science Foundation of China (General Project): Study on the role of exosome HMGB1 in promoting cervical cancer by regulating immune microenvironment, 2023-2026, hosted, in research

2. National Natural Science Foundation of China (Youth Project): Cohort Study on Exosomes Cell Adhesion Related Membrane Proteins and the Risk of Cervical Cancer, 2019-2021, hosted, completed.

3. National key research and development program of Shanxi Provincial Department of Science and Technology: Research on key technologies of mesenchymal stem cells for the treatment of drug-resistant tuberculosis, 2022-2025, hosted, in research.

4. Shanxi Provincial Health Commission " Four Batches " Scientific and Technological Innovation Project: Study on the Immunoregulatory Role of Mesenchymal Stem Cells in Anti-drug Resistant Tuberculosis, 2021-2023, hosted, in research.

5. Shanxi Province Returnees Special: Study on the role and mechanism of exosome miR-21 in the formation of cervical cancer, 2021-2022, hosted, in research.

6. Shanxi University Science and Technology Innovation Project, Exosome Membrane Protein in HPV Infection to Cervical Cancer Progression and Its Application in Cervical Cancer Screening Research, 2019-2021, hosted, completed.

7. Shanxi Provincial Natural Science Foundation (General Project): Study on the role of exosome Survivin protein in the progression of cervical lesions in HPV-infected patients, 2018-2020, hosted, completed.

Representative papers in recent five years

1. Dong L, Nygård M, Nathalie CS, Ole K, Hansen BT. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination. Int J Cancer, 2022.

2. Dong L, Nygård M, Hansen BT. Sociodemographic Correlates of Human Papillomavirus Vaccine Uptake: Opportunistic and Catch-Up Vaccination in Norway. Cancers, 2021, 13(3483): 1-13.

3. Yang C, Ma X, Dong L. Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients. J Med Virol. 2021,93(3):1639-1651.（corresponding author）

4. Ma XX, Ge A, Han J. Meta‑analysis of downregulated E‑cadherin as a diagnostic biomarker for cervical cancer. Archives of Gynecology and Obstetrics,2021,1(13):14-24. （corresponding author）

5. Han J, Ning P, Dong L. Association of polymorphisms of innate immunity-related genes and tuberculosis susceptibility in Mongolian population. Human Immunology, 2021 Feb（corresponding author）

6. Zhang SS, Dong L, Wang GM, et al. Progressive liver injury and increased mortality risk in COVID-19 patients: A retrospective cohort study in China. World J Gastroenterol, 2021,27(9): 835-853. (co-first author)

7. Dong L, Zhang L, Hu SY, et al. Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a ten-year prospective cohort study. Clinical Epigenetics,2020,3(1):1-8

8. Yin J, Dong L, Zhao J, et al. Composition and consistence of the bacterial microbiome in upper, middle and lower esophagus before and after Lugol’s iodine staining in the esophagus cancer screening. Scandinavian Journal of Gastroenterology, 2020, 55(12): 1467-1474. (co-first author)

9. Dong L, Li T, Li L, et al. Clustering patterns of type-type combination in multiple genotypes infections of human papillomavirus in cervical adenocarcinoma. Journal of Medical Virology,2019, 91(11):2001-2008.

10. Dong L, Yin J, Zhao J, et al. Microbial Similarity and Preference for Specific Sites in Healthy Oral Cavity and Esophagus. Frontier in Microbiology, 2018, 9:1603.

11. Dong L, Wang M, Zhao XL, et al. Human papillomavirus viral load as a useful tool for non-16/18 high-risk human papillomavirus positive women: a prospective screening cohort study. Gynecologic Oncology, 2018, 148(1):103-110.

12. Dong L, Hu SY, Zhang Q, et al. Risk prediction of cervical cancer and precancers by type-specific human papillomavirus: evidence from a population-based cohort study in China. Cancer Prevention Research, 2017,10(12):745-751.

13. Dong L, Lin CQ, Li L, et al. An evaluation of clinical performance of FTA cards for HPV 16/18 detection using cobas 4800 HPV Test compared to dry swab and liquid medium[J]. Journal of Clinical Virology, 2017, 94(8):67-71.

14. Dong L, Feng RM, Zhang LX, et al. Prospective comparison of hybrid capture 2 and SPF10-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. Journal of gynecologic oncology, 2017, 28(5): e66.

15. Zhang Q, Dong L, Hu SY, et al. Risk Stratification and Long-term Risk Prediction of E6 Oncoprotein in a Prospective Screening Cohort in China. International Journal of Cancer, 2017, 141(6):1110-1119.